Compare · CBLI vs MEDP
CBLI vs MEDP
Side-by-side comparison of Cleveland BioLabs, Inc. (CBLI) and Medpace Holdings Inc. (MEDP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLI and MEDP operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $17.14B, about 322.8x CBLI ($53.1M).
- MEDP has hit the wire 10 times in the past 4 weeks while CBLI has been quiet.
- MEDP has more recent analyst coverage (25 ratings vs 0 for CBLI).
- Company
- Cleveland BioLabs, Inc.
- Medpace Holdings Inc.
- Price
- -
- -
- Market cap
- $53.1M
- $17.14B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2006
- 2016
- News (4w)
- 0
- 10
- Recent ratings
- 0
- 25
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest CBLI
- SEC Form 4: Barbarick Steve K was granted 60,000 shares
- SEC Form 4: Verny Lea was granted 60,000 shares
- SEC Form DEF 14A filed by Cleveland BioLabs, Inc.
- SEC Form 4: Markvicka Taunia was granted 100,000 shares
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Cleveland BioLabs, Inc.
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest MEDP
- President & CEO Troendle August J. sold $9,969,094 worth of shares (15,978 units at $623.93), decreasing direct ownership by 3% to 545,217 units (SEC Form 4)
- CFO & Treasurer Brady Kevin M. exercised 3,400 shares at a strike of $138.87 and sold $2,125,816 worth of shares (3,400 units at $625.24) (SEC Form 4)
- President & CEO Troendle August J. sold $26,281,390 worth of shares (42,783 units at $614.30), decreasing direct ownership by 7% to 561,195 units (SEC Form 4)
- Director Carley Brian T sold $3,043,150 worth of shares (5,000 units at $608.63), decreasing direct ownership by 15% to 27,825 units (SEC Form 4)
- Director Davenport Fred B Jr exercised 7,583 shares at a strike of $116.08 and sold $4,414,590 worth of shares (7,283 units at $606.15), increasing direct ownership by 9% to 3,798 units (SEC Form 4)
- SEC Form 144 filed by Medpace Holdings Inc.
- President & CEO Troendle August J. sold $7,111,969 worth of shares (11,824 units at $601.49), decreasing direct ownership by 2% to 603,978 units (SEC Form 4)
- Director Mccarthy Cornelius P. Iii sold $690,122 worth of shares (1,140 units at $605.37), decreasing direct ownership by 8% to 12,275 units (SEC Form 4)
- President & CEO Troendle August J. sold $13,984,854 worth of shares (23,144 units at $604.25), decreasing direct ownership by 4% to 615,802 units (SEC Form 4)
- Director Mccarthy Cornelius P. Iii exercised 3,858 shares at a strike of $84.36 and sold $465,131 worth of shares (795 units at $585.07), increasing direct ownership by 30% to 13,415 units (SEC Form 4)